Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
1.880
-0.020 (-1.05%)
Oct 31, 2024, 4:00 PM EDT - Market closed

Acurx Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Selling, General & Admin
10.068.537.3410.782.42.42
Research & Development
6.676.044.752.032.23.51
Operating Expenses
16.7314.5812.0912.814.65.93
Operating Income
-16.73-14.58-12.09-12.81-4.6-5.93
EBT Excluding Unusual Items
-16.73-14.58-12.09-12.81-4.6-5.93
Other Unusual Items
---0.07--
Pretax Income
-16.73-14.58-12.09-12.75-4.6-5.93
Net Income
-16.73-14.58-12.09-12.75-4.6-5.93
Net Income to Common
-16.73-14.58-12.09-12.75-4.6-5.93
Shares Outstanding (Basic)
151311965
Shares Outstanding (Diluted)
151311965
Shares Change (YoY)
24.92%17.15%26.72%37.88%30.29%-
EPS (Basic)
-1.15-1.15-1.12-1.49-0.74-1.25
EPS (Diluted)
-1.15-1.15-1.12-1.49-0.74-1.25
Free Cash Flow
-12.23-9.8-7.54-5.01-3.35-3.99
Free Cash Flow Per Share
-0.84-0.77-0.70-0.59-0.54-0.84
EBIT
-16.73-14.58-12.09-12.81-4.6-5.93
Source: S&P Capital IQ. Standard template. Financial Sources.